Zobrazeno 1 - 10
of 74
pro vyhledávání: '"Bryan Dirks"'
Autor:
Mona Darwish, Bryan Dirks, Julie Passarell, David Jaworowicz, Sebastien Bihorel, Becky Howell, Joel Owen, Daryl DeKarske, Srdjan Stankovic
Publikováno v:
Clinical Pharmacology in Drug Development. 12:463-474
Autor:
Bryan, Dirks, Maurizio, Fava, Sarah D, Atkinson, Mark, Joyce, Michael E, Thase, Becky, Howell, Tim, Lin, Serge, Stankovic
Publikováno v:
Psychopharmacology bulletin. 52(4)
In a phase 2 study, pimavanserin demonstrated efficacy as adjunctive treatment for major depressive disorder (MDD). Subsequently, two phase 3 studies (NCT03968159 in the US; NCT03999918 in Europe) were initiated to examine the efficacy and safety of
Publikováno v:
Neuropsychiatric Disease and Treatment, Vol 2008, Iss Issue 5, Pp 949-958 (2008)
Ibrahim Turkoz, Cynthia A Bossie, Bryan Dirks, Carla M CanusoOrtho-McNeil Janssen Scientific Affairs, LLC, Titusville, NJ, USAAbstract: Direct and indirect effects of the new psychotropic paliperidone extended-release (paliperidone ER) tablets on neg
Externí odkaz:
https://doaj.org/article/a85737ed2de249969bd1778a236c12c1
Autor:
Marlene P. Freeman, Manish K. Jha, Srdjan Stankovic, Bryan Dirks, Maurizio Fava, Keith Liu, Madhukar H. Trivedi, George I. Papakostas, Michael E. Thase, Richard C. Shelton
Publikováno v:
Depression and Anxiety. 37:485-495
BACKGROUND Sexual dysfunction is common among patients with major depressive disorder (MDD). In the CLARITY study, the safety and efficacy of adjunctive pimavanserin, an inverse agonist at 5-HT2A receptors, were demonstrated when added to existing tr
Autor:
Michael Huss, Jeffrey H. Newcorn, Bryan Dirks, Keith McBurnett, Amaia Hervás, Caleb Bliss, Andrew J. Cutler, Joseph Gao
Publikováno v:
European Neuropsychopharmacology. 29:432-443
The present study investigated whether symptom reduction in children and adolescents with attention-deficit/hyperactivity disorder (ADHD) treated with guanfacine extended release (GXR) can be explained by sedative effects of the medication. Data from
Autor:
Marlene P. Freeman, Bryan Dirks, Richard C. Shelton, Manish K. Jha, Madhukar H. Trivedi, Keith Liu, Michael E. Thase, Srdjan Stankovic, Maurizio Fava, George I. Papakostas
Publikováno v:
The Journal of Clinical Psychiatry. 82
This was an analysis of the effect of pimavanserin, a 5-hydroxytryptamine-2A antagonist and inverse receptor agonist, on dysregulated sleep in patients with major depressive disorder (MDD) by DSM-5 criteria and an inadequate antidepressant response.F
Autor:
Keith Liu, Manish K. Jha, Richard C. Shelton, Srdjan Stankovic, Michael E. Thase, Madhukar H. Trivedi, George I. Papakostas, Maurizio Fava, Bryan Dirks, Marlene P. Freeman
Publikováno v:
Journal of affective disorders. 277
Background Up to 15% of patients with major depressive disorder (MDD) attempt suicide and up to 2% complete suicide. This was a post-hoc analysis aimed to evaluate the risk of suicide ideation and behavior associated with adjunctive pimavanserin trea
Autor:
Bryan Dirks, Jeffrey H. Newcorn, Brigitte Robertson, Michael Huss, J. Antoni Ramos-Quiroga, Joan Gu
Publikováno v:
European Child & Adolescent Psychiatry. 27:1283-1294
Data are reported from SPD503-318, a phase 3, open-label, safety study of guanfacine extended release (GXR) in European children and adolescents with attention-deficit/hyperactivity disorder (ADHD). Participants received dose-optimized GXR (1–7 mg/
Autor:
George I. Papakostas, Richard C. Shelton, Madhukar H. Trivedi, Bryan Dirks, Michael E. Thase, Srdjan Stankovic, Troy Whitworth, Maurizio Fava, Marlene P. Freeman, Manish K. Jha, Keith Liu
Publikováno v:
CNS Spectrums. 25:313-314
Study Objectives:Sexual dysfunction occurs in 40%-60% of patients with major depressive disorder (MDD), due to either the illness itself and/or the effects of antidepressant treatment. The phase-2 CLARITY trial recently demonstrated the efficacy of a
Autor:
Bryan Dirks, Srdjan Stankovic, Richard C. Shelton, George I. Papakostas, Maurizio Fava, Troy Whitworth, Michael E. Thase, Marlene P. Freeman, Madhukar H. Trivedi, Keith Liu
Publikováno v:
CNS Spectrums. 25:314-315
Study Objectives:Depression is the leading cause of disability worldwide, with fewer than 50% of treated patients achieving full remission. This study (“CLARITY,” ACP-103-042: NCT03018340) examined the 5-HT2A inverse agonist pimavanserin (PIM) as